<DOC>
	<DOCNO>NCT00754780</DOCNO>
	<brief_summary>The study phase II , open label trial oral Pirfenidone 24 adult patient neurofibromatosis type 1 . Pirfenidone new , broad-spectrum anti-fibrotic drug , proven vitro vivo negative effect fibroblast growth collagen matrix synthesis . Human study indicate promising therapeutic effect arrest reverse fibrosis variety different condition , excessive formation fibrous tissue major pathogenic mechanism . Since fibrous tissue significant component neurofibroma , reduction fibrosis could diminish tumor progression lead tumor shrinkage . Therefore , Pirfenidone excellent candidate treatment plexiform neurofibroma surgically unresectable tumor patient NF1 .</brief_summary>
	<brief_title>Clinical Trial Pirfenidone Adult Patients With Neurofibromatosis 1</brief_title>
	<detailed_description>Specific aim study : 1 . To evaluate efficacy Pirfenidone NF1 patient disfigure disable plexiform neurofibroma ( PN ) spinal neurofibroma ( SN ) 2 . To determine acute , subacute chronic toxicity Pirfenidone patient NF1 .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Diagnosis neurofibromatosis type I , base clinical criterion ( NIH Consensus Development Conference , 1988 ) . Tumors confirm histologically , since biopsy could cause change tumor growth interfere effect Pirfenidone treatment . Male female patient Age 18 year old All patient mentally capable sign consent form legal guardian provide consent Patients experience symptom neurofibromatous lesion refuse surgery good surgical candidate , plexiform neurofibroma experience significant discomfort , disfigurement nerve compression Presence multiple spinal neurofibroma surgical removal would carry major risk spinal cord damage . Tumors surgical removal could lead permanent ( longterm ) relief symptom Patients open skin lesion patient surgery contemplate surgery le 4 week start treatment Patients biopsy warrant suspected malignancy Individuals young 18 year Pregnant lactating woman Inability MR imaging ( e.g . claustrophobia , pacemaker allergy contrast dye , administration need neurofibroma image )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>NF1</keyword>
	<keyword>plexiform neurofibroma</keyword>
</DOC>